Menu
Recruiting NCT06217783

Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

No phase Interventional Oncologic Complications and Emergencies

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Introcan Safety IV Catheter.
Who it may be relevant to
Registry conditions: Oncologic Complications and Emergencies. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.

Detailed description

Primary Objectives:

\- The rate of catheter failure, defined as removal of the catheter for any reason other than "Care Complete" (i.e. a composite of removal due to "infiltration," "leaking," "catheter damage," "occlusion"), by day 10.

Secondary Objectives:

1. Time from catheter placement to removal (i.e. survival or dwell time). 2. Per catheter length rate of failure analysis 3. Rate of repeat catheterization 4. Rate of infection 5. Rate of thrombosis

Interventions

  • Device Introcan Safety IV Catheter
    Given by IV

Primary outcome measures

  • Safety and adverse events (AEs) [Time frame: Through study completion; an average of 1 year.]

Eligibility criteria

Inclusion criteria

  • Age > 18 years old.
  • Provision of signed and dated informed consent form.
  • Predetermined to have difficult IV access necessitating USIV placement
  • Expected admission to hospital with anticipated stay > 48 hours (per discussion with treating physician).

Exclusion criteria

  • Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician).
  • Inability to give informed consent.
  • Pregnant women.
  • Non-English speaking participants.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 1 center
  • MD Anderson Cancer Center — Houston

Identifiers

NCT: NCT06217783 · 2023-0848 · NCI-2024-00503

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗